Search Results

And we need that to do our best work.” – Ben Clements Mentorship Is the Engine of Science Ben chose

complexes and solute carriers, are relevant to immunology indications and rare diseases with high unmet need

The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where more data; they need clarity. The danger is subtle: 👉Scientific isolation feels busy, intelligent, respectable. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake. It feels like focus.

Each decision feels reasonable in isolation. Each step forward appears justified. No single decision feels reckless. No single leader feels accountable for the trajectory. Meetings feel heavier. Communication requires more explanation. Drift accelerates when everything feels important.

  ✅  You don’t need to abandon your scientific instincts. But you do need to adapt them if you want your startup to scale .     iterating, many scientific founders keep refining decks, processes, and team structures until they feel If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session

Complexity feels like progress. When everything feels important, nothing truly is. Leadership avoids saying no because every option feels valuable. More experiments feel safer than fewer deliberate ones.   Tradeoffs feel purposeful instead of arbitrary. Most importantly, order creates trust.

. 👉 It feels logical to evaluate success where it is most visible . Early in the year, decisions feel small. Flexible. Reversible. Assumptions feel too costly to challenge. Execution feels busy but not effective. Teams mistake motion for progress . Decisions no longer feel heavy. Tradeoffs feel intentional rather than painful.

Saying no to those opportunities feels counterintuitive. Each feels defensible. Each appears aligned with long-term value creation. Teams feel busy, but outcomes feel less decisive. Leadership conversations take longer. And this is where biotech fundraising begins to feel harder than it should. When ambition expands, leaders need explicit filters.

Plans that once felt flexible start to feel constrained. These signals are visible, concrete, and emotionally reassuring. 👉 They create the feeling that things Hiring decisions feel justified because the science is moving. Vendor contracts feel reasonable because the roadmap looks ambitious. Progress continues, activity stays high, and urgency feels manageable.

That feels logical. 👉 Complex biology seems to demand strong credentials.   The science is complex, the stakes are high, and mistakes feel expensive. . 👉 Strong resumes feel like protection against uncertainty. Founders feel the pressure to hold everything together. They operate inside it. 👉 This is why early-stage biotech hiring needs a different lens.

Business development conversations feel inconsistent, even when the company and the science have not The Symptoms of Unclear Biotech Positioning 👉 Most biotech founders feel that something is wrong in The logic feels intuitive. If the data is solid and the mechanism is novel, clarity should follow. External stakeholders no longer need to guess what matters most. This flexibility feels helpful, but it actually weakens trust , because external stakeholders cannot

A solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels They start by asking: What would FDA approval actually require from us, and what decisions need to reflect But you do need a framework for identifying and addressing regulatory gaps early . If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session

👉 In early-stage biotech, activity often feels like strategy. Internally, this feels manageable. Internally, this feels like diversification. Saying yes often feels safer than saying no. Letting go of a program can feel like abandoning potential value.

. 👉 We’re talking about the type of quiet misalignment that appears to be progress but feels like confusion People don’t need to vote on everything. They just need to understand what game they’re playing. But because it ensures everyone is solving the same problem. ✅ If your biotech startup feels like it’ If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session

2️⃣ Using buzzwords instead of clarity Words like “platform”, “breakthrough”, or “transformative” feel Frame the situation in terms of what’s at stake, whether that’s patient outcomes, time delays, unmet needs And when you focus on what your audience actually needs to hear, you don’t just earn attention, you earn If you're feeling the friction, indecision, misalignment, or slow momentum, it's not just operational Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session

Those courses didn’t feel like career-defining moments at the time — just requirements to pass. Early decisions don’t need to be perfect. They need to keep you moving. Curiosity compounds. You always need a scientific anchor — but you also need the courage to follow data where it leads. For real translational understanding, you need to see  the receptor in context.

This shift does not mean founders need more patents or heavier legal work. It stops because the IP creates unanswered questions that feel too expensive to explore further. lack of alignment between intellectual property and business intent. 2️⃣ Ownership and control that feel If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session

. 👉 Investor confidence softens  because the story feels reactive. 👉 BD partners disengage  because If you're feeling the friction — indecision, misalignment, slow momentum — it's not just operational. Whether you're refining your narrative, making tough tradeoffs, or simply feeling stuck, this session get you unstuck — fast. 👉 Book a 1:1 consult and start building the mindset your company actually needs

Surely more hands will move the needle. If you want your program to survive, you need a Blueprint for Precision. Not next quarter. audit — before your next DMTA cycle costs another $200K Let’s unlock the momentum your GPCR program needs

In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. What makes this pattern so hard to catch is that it feels productive. Meetings increase. Scientific nuance starts to feel inconvenient. By the time founders sense that something feels off, the logic has already normalized. 👉 The company

having to do 'everything at the same time ,' only for the youngest to wisely respond, 'No, you just need I understand that embracing a systematic approach can feel daunting, especially with the pressure to accelerate discovery . 🚀 Book your free 30-minute strategy call Let’s unlock the momentum your GPCR program needs

Watch Episode 172 What happens when the career you planned no longer feels right? It was mostly just because, I need to be back in the lab.” It’s rigorous pharmacology, but deeply tied to urgent public health needs.

You don’t need sharper eyesight. You need statistical methods that tell you, with confidence, whether the effect you’re seeing is real In This Session, You’ll Gain: ✅ The ability to calculate how many replicates you really  need for 95% What you need is a number that tells you whether those differences are real. How Many Replicates Do You Really Need? The second trap is habit.

week: industry insights, event updates, jobs, and classified publications—curated for scientists who need on leads that fail later in development In this exclusive session, Kenakin gives you the frameworks needed GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions Scientists, drug discovery teams, and pharmacologists who need curated, career-relevant updates.

This is embedded consulting for biotech and VC teams who need to move fast —without compromising scientific key decision. 🚀 Book your free 30-minute strategy call Let’s unlock the momentum your GPCR program needs insights = wasted time ✅ You can’t fail fas t if you can’t see the problems early ✅ Most teams don’t need more data— they need clarity ✅ Yamina’s Corner helps teams move from data chaos to decisive action

NHS esters are not very stable even in aqueous environment but they only need a slightly basic medium Not only do they work in aqueous medium, but also in aprotic solvents like DMF, where you will need to biggest advantage is the presence of Cys residues in proteins, although sometimes S-S bridge reduction is needed There’s no need for any catalysts; all reagents will be incorporated in the structure of the final compound

David Hodson needed molecules that were only one synthetic step beyond what JB was already making. It was a shared sense of fun, the kind of scientific joy that makes late-night imaging sessions feel lighter and big failures feel solvable.

The choice between these two depends on the results needed – but in case they are similar, fluorescent If you are curious about fluorescent probes, fluorescent probe design or GPCR tools, feel free to contact

Terry Kenakin’s latest lecture in Terry’s Corner  delivers exactly what your discovery teams need now Redefine your playbook:  Why Serafini believes that pain research needs to start from clinical phenotype GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who need Don’t Fall Behind—Access the Edge You Need 👉 Ready to sharpen your discovery decisions?

You don’t need more data—you need a way to translate snapshots into predictions. The lesson: models don’t just need data. They need the right data . , pharmacologists refining fundamentals, scientists challenging legacy assumptions, and leaders who need